Diagnosis and Potential Strategies to Discover New Drugs for the Treatment of Alzheimer’s Disease (AD)

Preview this chapter:

Diagnosis and Potential Strategies to Discover New Drugs for the Treatment of Alzheimer’s Disease (AD), Page 1 of 1

< Previous page | Next page > /docserver/preview/fulltext/9789815136142/chapter11-1.gif

Alzheimer disease (AD) is most common cause of dementia, which is characterized by impaired cognitive and behavioural charateristics. Deposition of Aβ plaques and neurofibrillary tangs (NFTs) are the hallmark of AD. Generally it is a chronic disease where neurodegeneration, and loss of neuronal function arise earlier before it is diagnosed. Early detection of AD is important as it reduces the severity of the disease. In this regard, an effective tools/methods are available including CSF biomarkers, Magnetic Resonance imaging (MRI), Positron emission tomography (PET) but all these methods are painful and often cannot be afforded by the patients. <br><br>Therapy of AD includes inhibitors of choline esterases, and antagonists at NMDA receptors. From the studies it is shown that these drugs just offer relief from symptoms rather than alleviating the progression of disease. Multiple pathological processes contribute for AD, like oxidative stress, dysregulation of neurotransmitters, inflammation of neurons, aggregation β-amyloid, phosphorylation of tau protein. It is essential to target multiple causes for an effective outcome in the treatment of AD. Early diagnosis is also crucial as it reduces disease progression thereby cost involved in AD therapy. <br><br>This review focuses on non-invasive, patient affordable diagnosis methods and also potential targets to discover new drugs beyond conventional and available drugs.<br>